- Posted August 6, 2013 by Irl B. Hirsch, MDOver the past six months we have had more questions than answers about the risk of incretin therapy (DPP-4 inhibitors and GLP-1 agonists) and the increased risks for both pancreatitis and pancreatic carcinoma. The discussion seems to have resolved to an interim and perhaps temporary conclusion based on the recent American Diabetes Association Scientific Sessions in Chicago in June.At that conference Dr.
- Posted July 25, 2013 by Doron Schneider, MD, FACP
- Posted July 24, 2013 by John L. Leahy, MD
- Posted June 25, 2013 by Joseph Largay, PA-C, CDE
With all the things I have to cover during my 20 minute follow-up visits with my patients with diabetes, I sometimes struggle with whether or not to interrupt as they tell me about something that, at first, seems irrelevant, at least to me.
I do, however, enjoy most of these discussions as I learn about their recent to Hawaii or some fishing trip. I do enjoy living vicariously through the lives of my patients!
- Posted June 12, 2013 by John L. Leahy, MD
Doron Schneider, MD and Jack Leahy, MD discuss the importance of patient BMI and other risk factors for coronary artery disease when weighing treatment options.
- Posted May 29, 2013 by John L. Leahy, MD
Dr. Jack Leahy, endocrinologist and general internist, Dr. Doron Schneider, weigh different initial treatment options presented by leading endocrinologists Silvio Inzucchi, MD, Alan J. Garber, MD and Laurence Kennedy, MD
- Posted May 16, 2013 by Jay Shubrook, DO, FACOFP, FAAFP
Case 6—A Newly Diagnosed Patient with a High BMI—is a very common scenario for the primary care physician. There are a number of issues worth highlighting before I outline my suggestions for treatment.
- Posted March 19, 2013 by Doron Schneider, MD, FACPIt is certainly a new world. As a result of healthcare reform the landscape of diabetes care has forever been altered. The practicing clinician, patient and healthcare administrators all need to have a firm grasp of these new realities if they wish to prosper now and into the future. In this blog post I intend to provide a high level overview of the different ways that diabetes care is affected in this brave new world.Patients· Insurance coverage – patients will now be provided expanded insurance
- Posted March 18, 2013 by Jay Shubrook, DO, FACOFP, FAAFP
There is almost no other disease as pervasive as type 2 diabetes, a disease that has touched almost every family in America. Although there was a time when we had limited management tools, we now have ten classes of medications plus many kinds of insulin available as options. The result is a choice of many treatment combinations, which, however welcome, can also be overwhelming for the practicing physician. With so many choices it becomes very hard to decide what comes after metformin.
- Posted January 17, 2013 by John L. Leahy, MD(Full disclosure – I am an Advisor to Janssen pharmaceuticals that makes canagliflozin)An FDA advisory panel last week reviewed canagliflozin, with the majority recommending approval. Canaglifozin is the first member of a new class of oral medications for type 2 diabetes–sodium-glucose co-transportor-2 (SGLT2) inhibitors–that will likely make it to the U.S. market.